Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor
Autore:
Beljaars, L; Molema, G; Schuppan, D; Geerts, A; De Bleser, PJ; Weert, B; Meijer, DKF; Poelstra, K;
Indirizzi:
Univ Groningen, Inst Drug Explorat, Dept Pharmacokinet & Drug Delivery, Ctr Pharm, NL-9713 AV Groningen, Netherlands Univ Groningen Groningen Netherlands NL-9713 AV V Groningen, Netherlands Univ Erlangen Nurnberg, Med Klin 1, D-90154 Erlangen, Germany Univ Erlangen Nurnberg Erlangen Germany D-90154 -90154 Erlangen, Germany Free Univ Brussels, Cell Biol & Histol Lab, B-1090 Brussels, Belgium Free Univ Brussels Brussels Belgium B-1090 Lab, B-1090 Brussels, Belgium
Titolo Testata:
JOURNAL OF BIOLOGICAL CHEMISTRY
fascicolo: 17, volume: 275, anno: 2000,
pagine: 12743 - 12751
SICI:
0021-9258(20000428)275:17<12743:STTRHS>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXPERIMENTAL LIVER FIBROSIS; MONOCLONAL-ANTIBODIES; LYSOSOMAL-ENZYMES; FIBROBLASTS; CIRRHOSIS; INTEGRINS; ADHESION; PROTEIN; MATRIX; RGD;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
53
Recensione:
Indirizzi per estratti:
Indirizzo: Beljaars, L Univ Groningen, Inst Drug Explorat, Dept Pharmacokinet & Drug Delivery, Ctr Pharm, Ant Deusinglaan 1, NL-9713 AV Groningen, Netherlands Univ Groningen Ant Deusinglaan 1 Groningen Netherlands NL-9713 AV
Citazione:
L. Beljaars et al., "Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor", J BIOL CHEM, 275(17), 2000, pp. 12743-12751

Abstract

The key pathogenic event in liver fibrosis is the activation of hepatic stellate cells (HSC). Consequently, new antifibrotic therapies are directed toward an inhibition of HSC activities. The aim of the present study was to develop a drug carrier to HSC, which would allow cell-specific delivery of antifibrotic drugs thus enhancing their effectiveness in vivo. We modified human serum albumin (HSA) with 10 cyclic peptide moieties recognizing collagen type VI receptors (C*GRGDSPC*, in which C* denotes the cyclizing cysteine residues) yielding pCVI-HSA. In vivo experiments showed preferential distribution of pCVI-HSA to both fibrotic and normal rat livers (respectively,62 +/- 6 and 75 +/- 16% of the dose at 10 min after intravenous injection), Immunohistochemical analysis demonstrated that pCVI-HSA predominantly bound to HSC in fibrotic livers (73 +/- 14%). In contrast, endothelial cells contributed mostly to the total liver accumulation in normal rats. In vitro studies showed that pCVI-HSA specifically bound to rat HSC, in particular to the activated cells, and showed internalization of pCVI-HSA by these cells. in conclusion, pCVI-HSA may be applied as a carrier to deliver antifibrotic agents to HSC, which may strongly enhance the effectiveness and tissue selectivity of these drugs. This approach has the additional benefit that such carriers may block receptors that play a putative role in the pathogenesis of liver fibrosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 11:28:50